MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$952,000
EPS
-$0.41
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue
0
0
3,000
0
Research and development
388,000
427,000
362,000
469,000
General and administrative
564,000
585,000
548,000
718,000
Total operating expenses
952,000
1,012,000
910,000
1,187,000
Loss from operations
-952,000
-1,012,000
-907,000
-1,187,000
Change in fair value of warrant liability
0
-
0
0
Other income (expense), net
0
6,000
14,000
28,000
Other income (expense), net
0
-
14,000
28,000
Net loss
-952,000
-1,006,000
-893,000
-1,159,000
Basic EPS
-0.41
-0.59
-0.383
-0.55
Diluted EPS
-0.41
-0.59
-0.383
-0.55
Basic Average Shares
2,431,695
1,948,357
2,332,792
2,183,039
Diluted Average Shares
2,431,695
1,948,357
2,332,792
2,183,039
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$952,000
(9.42%↑ Y/Y)
Loss from operations
-$952,000
(8.37%↑ Y/Y)
Total operating
expenses
$952,000
(-8.37%↓ Y/Y)
General and
administrative
$564,000
(-33.96%↓ Y/Y)
Research and development
$388,000
(109.73%↑ Y/Y)
Buy us a coffee
Alaunos Therapeutics, Inc. (TCRT)
Alaunos Therapeutics, Inc. (TCRT)